Juvenile myelomonocytic leukemia (JMML) is a unique, aggressive hematopoietic disorder
of infancy/early childhood caused by excessive proliferation of cells of monocytic and …

Juvenile myelomonocytic leukemia (JMML) is a unique clonal hematopoietic disorder of
early childhood. It is classified as an overlap myeloproliferative/myelodysplastic neoplasm …

RAS genes encode a family of 21 kDa proteins that are an essential hub for a number of
survival, proliferation, differentiation and senescence pathways. Signaling of the RAS …

Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative disorder of
early childhood characterized by mutations activating RAS signaling. Established clinical …

Clear cell renal cell carcinomas (ccRCCs) display divergent clinical behaviours. Molecular
markers might improve risk stratification of ccRCC. Here we use, based on genome-wide …

Purpose: Known clinical and genetic markers have limitations in predicting disease course
and outcome in juvenile myelomonocytic leukemia (JMML). DNA methylation patterns in …

Juvenile myelomonocytic leukemia (JMML), a rare and aggressive myelodysplastic/
myeloproliferative neoplasm that occurs in infants and during early childhood, is …

Juvenile myelomonocytic leukemia (JMML) is a unique clonal hematopoietic disorder of
early childhood characterized by hyperactivation of the RAS signal transduction pathway …

Juvenile myelomonocytic leukemia (JMML) is a typically aggressive myeloid neoplasm of
childhood that is clinically characterized by overproduction of monocytic cells that can …

Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative disorder of childhood
caused by mutations in the Ras pathway. Outcomes in JMML vary markedly from …